[A24-13] Ublituximab (multiple sclerosis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2024
Project no.:
A24-13
Commission:
Commission awarded on 30.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features
- Patients who have not yet received disease-modifying therapy and show no evidence of a severe course of disease: added benefit not proven
- Patients who have not yet received disease-modifying therapy and show evidence of a severe course of disease and adults who show an active course of disease despite treatment with a disease-modifying therapy: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-13_en
| Project no. | Title | Status |
|---|---|---|
| G24-14 | Ublituximab (multiple sclerosis) – 2nd Addendum to Project A24-13 | Commission completed |
| A24-68 | Ublituximab (multiple sclerosis) – Addendum to Project A24-13 | Commission completed |
Federal Joint Committee (G-BA)
01-08-2024 A G-BA decision was published.
G-BA documents on this decision